Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen acquires KAI pharmaceuticals
The acquisition, which was initially announced on 10 April 2012, includes KAI’s main product KAI-4169, an agent being studied to treat secondary hyperparathyroidism in patients with chronic kidney
The acquisition, which was initially announced on 10 April 2012, includes KAI’s main product KAI-4169, an agent being studied to treat secondary hyperparathyroidism in patients with chronic kidney
Amitiza is a prostone, a local activator of type-2 chloride ion channels (ClC-2) in cells lining the small intestine. In September 2010, a marketing application was submitted to
With the new acquisition, Renaissance has access to world-class semi-solid, liquid, and sterile pharmaceutical contract development and manufacturing capabilities of DPT Laboratories. Under the deal, the current shareholders
As part of the collaboration, Prosonix will work closely with Omar Usmani, an internationally recognised expert in respiratory diseases and inhaled drug delivery at the college’s National Heart
T2D is one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world. Under the terms of the license, SatRx has received
Under the agreement, Medunik Canada will distribute Orphan’s four therapies for certain medical conditions including acute hepatic porphyria, hyperammonaema due to N-acetylglutamate synthase (NAGS) deficiency or one of
Lupin’s generic equivalent of Lyrica capsules are manufactured as Pregabalin Capsules with dosage forms of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225
The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) and Vascular Endothelial Growth Factor Receptor 3 (VEGFR3), was compared with that of CTx-0294945, a potent
The company has randomised 75 patients with Hereditary Angioedema (HAE) in its ongoing US pivotal Study 1310, out of which 53 experienced a repeat attack or achieved a
The open-label, multicenter studies will evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc and rFIXFc in previously-treated children with severe hemophilia A or B under the age of